[11] In the first half of the 2010s, Bellevue Group persistently declining profit margins and thus amended their strategy to focus on institutional asset management.

[13] With the acquisition of the asset manager StarCapital AG in 2016, founded in 1996 and based in the Frankfurt am Main area, for an estimated CHF 30 to 40 million, the Bellevue Group aimed to increase its presence in Germany.

[18] Effective 1 January 2018, Bellevue Group’s subsidiary StarCapital acquired the German investment company Mars Asset Management to expand its business with institutional investors.

[20] In 2018, the venture capital fund BB Pureos Bioventures was established,[22] which is registered on the Channel Island of Guernsey and focuses on the development of new biological active substances for medicines targeting indications with high medical need such as nucleic acid, cell- and gene therapies.

[29] In this context, the Adbodmer AG, founded in 2001 by Adriana Ospel-Bodmer, the wife of former UBS President Marcel Ospel,[30] became part of the Bellevue Group.

[31] In 2019, the subsidiary Bank am Bellevue was sold to the Luxembourg KBL Group, thereby abandoning the private client business that had been built up in previous years.

[34][35] With the onset of the Covid-19 pandemic in spring 2020, there was a heightened demand for investments in the health sector, and the operating result increased by around 15% to CHF 17.5 million in the first half of 2020.

[37][38] Primarily due to rising interest rates, which also affected small biotech companies in which the Bellevue Group invests, the market conditions weakened again in 2022.

[43] Additionally, the fund Bellevue AI Health (Lux) was launched, which focuses on generative artificial intelligence (GenAI) and the investment opportunities arising from it in the healthcare sector.

[8] In the area of alternative investments in Swiss SMEs, Bellevue Group reached CHF 1 billion in managed client assets in 2021.